Skip to content
Screener

Comstock Inc. LODE Bioleum — Research And Development Expense

Other segment segments

Corporate And Other
$162.1K-37.6%

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.73M+127%

Other financials

Income statement

See full
Revenue$272.8K-19.7%
Gross profit-$896.1K-88.9%
Operating income-$26.9M-251%
Net income-$25.5M-225%
EPS (diluted)-$3.01-450%

Balance sheet

See full
Cash & equivalents$31.4M+69.0%
Total debt$19.4M+4.0%
Total equity$137.3M+55.1%
Total assets$193.5M+30.6%

Cash flow

See full
Operating cash flow-$10.1M-110%
CapEx--100%
Free cash flow-$3.5M+2.7%

Valuation

See full
Market cap$246.98M+150%
Enterprise value$234.98M+137%
P/S243.4×+213×

Profitability

See full
Gross margin-165.6%-200pp
Operating margin-5,846.1%-8,341pp
Net margin-6,012.3%-9,757pp
FCF margin-462.3%-171pp

Returns & leverage

See full
Return on equity-54%-8.7pp
Debt / equity0.1×-0.1×
Current ratio3.2×+1.7×

Where this comes from

Reported directly by Comstock Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Comstock Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437749-26-024304
Three-Months Ended / June 30, 2026MetalsMining(1)Strategic InvestmentsCorporate / OtherTotal of Segments before Bioleum Corp.BioleumConsolidated
Cost of goods sold$1,168,897$1,168,897$1,168,897
Selling and marketing$112,276$233,959$346,235$1,389$347,624
General and administrative$1,419,136$630,828$3,238$2,572,589$4,625,791$2,376,255$7,002,046
Research and development$1,019,577$366$1,019,943$1,264,420$2,284,363
Depreciation and amortization$71,807$2,330$1,208$75,345$945,415$1,020,760
Loss on intangible assets impairment$13,648,042$13,648,042
Loss on property, plant and equipment impairment$1,736,481$1,736,481
Loss from operations$(3,556,619)$(600,274)$(3,238)$(2,803,256)$(6,963,387)$(19,972,002)$(26,935,389)

Document

FAQ

What is Comstock Inc.'s bioleum — research and development expense?
Comstock Inc. (LODE) reported bioleum — research and development expense of $1.26M in Q2 2026.
How has Comstock Inc.'s bioleum — research and development expense changed year-over-year?
Comstock Inc.'s bioleum — research and development expense decreased by 34.2% year-over-year, from $1.92M to $1.26M.
What does bioleum — research and development expense mean?
Represents expenditures dedicated to the innovation, design, and testing of new technologies or processes within the Bioleum segment. High levels of this expense indicate a focus on long-term technological advancement and future product viability.

Ask your AI about Comstock Inc.'s bioleum — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude